In Kazakhstan, The Timing Of The Start Of Vaccination With "Sputnik V" Has Been Clarified

In Kazakhstan, The Timing Of The Start Of Vaccination With "Sputnik V" Has Been Clarified
In Kazakhstan, The Timing Of The Start Of Vaccination With "Sputnik V" Has Been Clarified

Video: In Kazakhstan, The Timing Of The Start Of Vaccination With "Sputnik V" Has Been Clarified

Отличия серверных жестких дисков от десктопных
Video: ‘Sputnik V, Sputnik Lite are reliable like Kalashnikovs…’: Russian deputy Envoy 2023, February
Anonim
Image
Image

NUR-SULTAN, January 13 - RIA Novosti. Kazakhstan plans to begin vaccination with the Russian Sputnik V vaccine at the end of February, the production of which has been established in the republic, Acting Deputy Chairman of the Medical and Pharmaceutical Control Committee Nurlybek Asylbekov said on Wednesday.

Earlier, the press service of the government reported that Kazakhstan will begin mass vaccination with its vaccine in March. In addition, on December 21, 2020, the production of the Russian Sputnik V vaccine was launched at the Karaganda pharmaceutical complex (in central Kazakhstan). An experimental batch of Sputnik V vaccines in the amount of 6 thousand doses was sent to the Russian Federation for quality control. It was reported that the republic plans to begin mass vaccination with the Russian vaccine in February.

"According to the planned schedule, if there are positive results (quality checks - ed.), The Karaganda pharmaceutical complex will already develop industrial batches, we hope that by the end of February there may be a batch of vaccines for vaccination," Asylbekov said at a briefing.

He added that the republic has not yet received the results of checking the quality of the batch of vaccines that were sent to the Russian Federation, the procedure may take up to a month.

In August, the Russian Ministry of Health registered the world's first vaccine for the prevention of COVID-19, developed by the Gamaleya Research Center for Electrochemistry. It was named "Sputnik V". The vaccine is based on a well-studied and validated human adenoviral vector platform, the important benefits of which are safety, efficacy and no long-term adverse effects.

Currently, the third phase of clinical trials has been approved and is being carried out in Belarus, the United Arab Emirates, Venezuela and a number of other countries. More than 50 countries have received bids for more than 1.2 billion doses of Sputnik V vaccine.

The latest data on the situation with COVID-19 in Russia and the world are presented on the stopkoronavirus.ru portal.

Popular by topic